KOD announced Zenkuda and tabirafusp-ted met primary endpoints in Phase 3 DAYBREAK for wet AMD. Zenkuda now has five positive Phase 3 studies. BLA planned for 4Q26. KSI-101 data due December.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
